0	5	Tumor	tumor	NN
6	14	necrosis	necrosis	NN
15	21	factor	factor	NN
22	27	alpha	alpha	NN
28	37	decreases	decrease	VBZ
37	38	,	,	,
39	42	and	and	CC
43	57	interleukin-10	interleukin-10	NN
58	67	increases	increase	NNS
67	68	,	,	,
69	72	the	the	DT
73	84	sensitivity	sensitivity	NN
85	87	of	of	IN
88	93	human	human	JJ
94	103	monocytes	monocyte	NNS
104	106	to	to	TO
107	120	dexamethasone	dexamethasone	NN
120	121	:	:	:
122	131	potential	potential	JJ
132	142	regulation	regulation	NN
143	145	of	of	IN
146	149	the	the	DT
150	164	glucocorticoid	glucocorticoid	NN
165	173	receptor	receptor	NN
173	174	.	.	.

176	186	Resistance	resistance	NN
187	189	to	to	TO
190	204	glucocorticoid	glucocorticoid	NN
205	212	therapy	therapy	NN
213	216	has	have	VBZ
217	221	been	be	VBN
222	230	observed	observe	VBN
231	233	in	in	IN
234	242	patients	patient	NNS
243	247	with	with	IN
248	271	autoimmune/inflammatory	autoimmune/inflammatory	JJ
272	280	diseases	disease	NNS
281	284	and	and	CC
285	288	may	may	MD
289	291	be	be	VB
292	299	related	related	JJ
300	302	to	to	TO
303	306	the	the	DT
307	319	inflammatory	inflammatory	JJ
320	327	process	process	NN
328	334	itself	itself	PRP
334	335	.	.	.

336	339	The	the	DT
340	343	aim	aim	NN
344	346	of	of	IN
347	351	this	this	DT
352	357	study	study	NN
358	361	was	be	VBD
362	364	to	to	TO
365	372	examine	examine	VB
373	376	the	the	DT
377	384	ability	ability	NN
385	387	of	of	IN
388	393	tumor	tumor	NN
394	402	necrosis	necrosis	NN
403	409	factor	factor	NN
410	415	alpha	alpha	NN
416	417	(	(	(
417	425	TNFalpha	TNFalpha	NNP
425	426	,	,	,
427	428	a	a	DT
429	444	proinflammatory	proinflammatory	JJ
445	453	cytokine	cytokine	NN
453	454	)	)	)
455	458	and	and	CC
459	470	interleukin	interleukin	NN
471	472	(	(	(
472	478	IL)-10	IL)-10	NNP
479	480	(	(	(
480	482	an	an	DT
483	500	anti-inflammatory	anti-inflammatory	JJ
501	509	cytokine	cytokine	NN
509	510	)	)	)
511	513	to	to	TO
514	528	differentially	differentially	RB
529	537	regulate	regulate	VB
538	541	the	the	DT
542	553	sensitivity	sensitivity	NN
554	556	of	of	IN
557	562	human	human	JJ
563	584	monocytes/macrophages	monocytes/macrophage	NNS
585	587	to	to	TO
588	603	glucocorticoids	glucocorticoid	NNS
603	604	.	.	.

605	607	To	to	TO
608	618	accomplish	accomplish	VB
619	623	this	this	DT
623	624	,	,	,
625	627	we	we	PRP
628	633	first	first	RB
634	642	analyzed	analyze	VBD
643	646	the	the	DT
647	654	pattern	pattern	NN
655	657	of	of	IN
658	666	TNFalpha	TNFalpha	NNP
667	670	and	and	CC
671	676	IL-10	IL-10	NNP
677	687	inhibition	inhibition	NN
688	690	by	by	IN
691	704	dexamethasone	dexamethasone	NN
705	707	in	in	IN
708	722	LPS-stimulated	lps-stimulated	JJ
723	734	whole-blood	whole-blood	JJ
735	739	cell	cell	NN
740	748	cultures	culture	NNS
748	749	.	.	.

750	756	Second	second	RB
756	757	,	,	,
758	760	we	we	PRP
761	768	studied	study	VBD
769	772	the	the	DT
773	783	modulation	modulation	NN
784	786	of	of	IN
787	790	the	the	DT
791	802	sensitivity	sensitivity	NN
803	805	of	of	IN
806	811	these	these	DT
812	817	cells	cell	NNS
818	820	to	to	TO
821	834	dexamethasone	dexamethasone	NN
835	837	by	by	IN
838	851	preincubation	preincubation	NN
852	856	with	with	IN
857	865	TNFalpha	TNFalpha	NNP
866	868	or	or	CC
869	874	IL-10	IL-10	NNP
875	878	and	and	CC
879	890	measurement	measurement	NN
891	893	of	of	IN
894	908	LPS-stimulated	lps-stimulated	JJ
909	913	IL-6	il-6	NN
914	923	secretion	secretion	NN
923	924	.	.	.

925	927	In	in	IN
928	936	addition	addition	NN
936	937	,	,	,
938	940	we	we	PRP
941	950	evaluated	evaluate	VBD
951	954	the	the	DT
955	961	effect	effect	NN
962	964	of	of	IN
965	978	dexamethasone	dexamethasone	NN
979	981	on	on	IN
982	1017	phorbolmyristate-acetate-stimulated	phorbolmyristate-acetate-stimulated	JJ
1018	1022	IL-1	il-1	NN
1023	1031	receptor	receptor	NN
1032	1042	antagonist	antagonist	NN
1043	1052	secretion	secretion	NN
1053	1055	by	by	IN
1056	1059	the	the	DT
1060	1065	human	human	JJ
1066	1075	monocytic	monocytic	JJ
1076	1080	cell	cell	NN
1081	1085	line	line	NN
1086	1090	U937	u937	NN
1090	1091	.	.	.

1092	1099	Finally	finally	RB
1099	1100	,	,	,
1101	1103	we	we	PRP
1104	1116	investigated	investigate	VBD
1117	1124	whether	whether	IN
1125	1128	the	the	DT
1129	1139	modulation	modulation	NN
1140	1142	of	of	IN
1143	1161	corticosensitivity	corticosensitivity	NN
1162	1164	in	in	IN
1165	1174	TNFalpha-	tnfalpha-	NN
1175	1178	and	and	CC
1179	1195	IL-10-pretreated	il-10-pretreated	JJ
1196	1200	U937	u937	NN
1201	1206	cells	cell	NNS
1207	1210	was	be	VBD
1211	1218	related	relate	VBN
1219	1221	to	to	TO
1222	1223	a	a	DT
1224	1230	change	change	NN
1231	1233	of	of	IN
1234	1237	the	the	DT
1238	1252	glucocorticoid	glucocorticoid	NN
1253	1261	receptor	receptor	NN
1262	1275	concentration	concentration	NN
1276	1279	and	and	CC
1280	1288	affinity	affinity	NN
1288	1289	.	.	.

1290	1303	Dexamethasone	Dexamethasone	NNP
1304	1307	had	have	VBD
1308	1317	different	different	JJ
1318	1325	effects	effect	NNS
1326	1328	on	on	IN
1329	1340	LPS-induced	lps-induced	JJ
1341	1349	TNFalpha	TNFalpha	NNP
1350	1353	and	and	CC
1354	1359	IL-10	IL-10	NNP
1360	1369	secretion	secretion	NN
1369	1370	;	;	:
1371	1378	whereas	whereas	IN
1379	1381	it	it	PRP
1382	1392	suppressed	suppress	VBD
1393	1401	TNFalpha	TNFalpha	NNP
1402	1404	in	in	IN
1405	1406	a	a	DT
1407	1421	dose-dependent	dose-dependent	JJ
1422	1429	fashion	fashion	NN
1429	1430	,	,	,
1431	1434	its	its	PRP$
1435	1441	effect	effect	NN
1442	1444	on	on	IN
1445	1450	IL-10	IL-10	NNP
1451	1460	secretion	secretion	NN
1461	1464	was	be	VBD
1465	1473	biphasic	biphasic	JJ
1473	1474	,	,	,
1475	1484	producing	produce	VBG
1485	1496	stimulation	stimulation	NN
1497	1499	at	at	IN
1500	1505	lower	low	JJR
1505	1506	,	,	,
1507	1510	and	and	CC
1511	1521	inhibition	inhibition	NN
1522	1524	at	at	IN
1525	1531	higher	high	JJR
1532	1537	doses	dose	NNS
1537	1538	.	.	.

1539	1542	The	the	DT
1543	1556	concentration	concentration	NN
1557	1559	of	of	IN
1560	1563	LPS	lps	NN
1564	1572	employed	employ	VBN
1573	1583	influenced	influence	VBD
1584	1587	the	the	DT
1588	1594	effect	effect	NN
1595	1597	of	of	IN
1598	1611	dexamethasone	dexamethasone	NN
1612	1614	on	on	IN
1615	1620	IL-10	IL-10	NNP
1621	1630	secretion	secretion	NN
1631	1632	(	(	(
1632	1633	P	p	NN
1634	1635	<	<	SYM
1636	1641	0.001	0.001	CD
1641	1642	)	)	)
1642	1643	.	.	.

1644	1656	Pretreatment	Pretreatment	NNP
1657	1661	with	with	IN
1662	1670	TNFalpha	TNFalpha	NNP
1671	1681	diminished	diminish	VBD
1681	1682	,	,	,
1683	1686	and	and	CC
1687	1691	with	with	IN
1692	1697	IL-10	IL-10	NNP
1698	1706	improved	improve	VBD
1706	1707	,	,	,
1708	1711	the	the	DT
1712	1719	ability	ability	NN
1720	1722	of	of	IN
1723	1736	dexamethasone	dexamethasone	NN
1737	1739	to	to	TO
1740	1748	suppress	suppress	VB
1749	1753	IL-6	il-6	NN
1754	1763	secretion	secretion	NN
1764	1766	in	in	IN
1767	1778	whole-blood	whole-blood	JJ
1779	1783	cell	cell	NN
1784	1792	cultures	culture	NNS
1793	1794	(	(	(
1794	1795	P	p	NN
1796	1797	<	<	JJR
1798	1802	0.01	0.01	CD
1803	1806	for	for	IN
1807	1811	both	both	DT
1811	1812	)	)	)
1813	1816	and	and	CC
1817	1819	to	to	TO
1820	1827	enhance	enhance	VB
1828	1832	IL-1	il-1	NN
1833	1841	receptor	receptor	NN
1842	1852	antagonist	antagonist	NN
1853	1862	secretion	secretion	NN
1863	1865	by	by	IN
1866	1870	U937	u937	NN
1871	1876	cells	cell	NNS
1877	1878	(	(	(
1878	1879	P	p	NN
1880	1881	<	<	JJR
1882	1886	0.05	0.05	CD
1887	1890	for	for	IN
1891	1895	both	both	DT
1895	1896	)	)	)
1896	1897	.	.	.

1898	1906	TNFalpha	TNFalpha	NNP
1907	1916	decreased	decrease	VBD
1917	1918	(	(	(
1918	1919	P	p	NN
1920	1921	<	<	SYM
1922	1927	0.001	0.001	CD
1927	1928	)	)	)
1928	1929	,	,	,
1930	1935	while	while	IN
1936	1941	IL-10	IL-10	NNP
1942	1951	increased	increase	VBD
1952	1953	(	(	(
1953	1954	P	p	NN
1955	1956	<	<	SYM
1957	1962	0.001	0.001	CD
1962	1963	)	)	)
1963	1964	,	,	,
1965	1968	the	the	DT
1969	1982	concentration	concentration	NN
1983	1985	of	of	IN
1986	1999	dexamethasone	dexamethasone	NN
2000	2007	binding	binding	NN
2008	2013	sites	site	NNS
2014	2016	in	in	IN
2017	2022	these	these	DT
2023	2028	cells	cell	NNS
2028	2029	,	,	,
2030	2034	with	with	IN
2035	2037	no	no	DT
2038	2049	discernible	discernible	JJ
2050	2056	effect	effect	NN
2057	2059	on	on	IN
2060	2065	their	their	PRP$
2066	2073	binding	binding	NN
2074	2082	affinity	affinity	NN
2082	2083	.	.	.

2084	2086	We	we	PRP
2087	2095	conclude	conclude	VBP
2096	2100	that	that	IN
2101	2116	glucocorticoids	glucocorticoid	NNS
2117	2131	differentially	differentially	RB
2132	2140	modulate	modulate	VBP
2141	2149	TNFalpha	TNFalpha	NNP
2150	2153	and	and	CC
2154	2159	IL-10	IL-10	NNP
2160	2169	secretion	secretion	NN
2170	2172	by	by	IN
2173	2178	human	human	JJ
2179	2188	monocytes	monocyte	NNS
2189	2191	in	in	IN
2192	2193	a	a	DT
2194	2197	LPS	LPS	NNP
2198	2212	dose-dependent	dose-dependent	JJ
2213	2220	fashion	fashion	NN
2221	2224	and	and	CC
2225	2229	that	that	IN
2230	2233	the	the	DT
2234	2245	sensitivity	sensitivity	NN
2246	2248	of	of	IN
2249	2254	these	these	DT
2255	2260	cells	cell	NNS
2261	2263	to	to	TO
2264	2279	glucocorticoids	glucocorticoid	NNS
2280	2282	is	be	VBZ
2283	2290	altered	alter	VBN
2291	2293	by	by	IN
2294	2302	TNFalpha	TNFalpha	NNP
2303	2305	or	or	CC
2306	2311	IL-10	IL-10	NNP
2312	2324	pretreatment	pretreatment	NN
2324	2325	;	;	:
2326	2334	TNFalpha	TNFalpha	NNP
2335	2341	blocks	block	VBZ
2342	2347	their	their	PRP$
2348	2355	effects	effect	NNS
2355	2356	,	,	,
2357	2364	whereas	whereas	IN
2365	2370	IL-10	IL-10	NNP
2371	2375	acts	act	VBZ
2376	2391	synergistically	synergistically	RB
2392	2396	with	with	IN
2397	2412	glucocorticoids	glucocorticoid	NNS
2412	2413	.	.	.

2414	2418	This	this	DT
2419	2421	is	be	VBZ
2422	2433	accompanied	accompany	VBN
2434	2436	by	by	IN
2437	2445	opposite	opposite	JJ
2446	2460	glucocorticoid	glucocorticoid	NN
2461	2469	receptor	receptor	NN
2470	2477	changes	change	NNS
2477	2478	,	,	,
2479	2491	respectively	respectively	RB
2492	2500	opposing	oppose	VBG
2501	2504	and	and	CC
2505	2513	favoring	favor	VBG
2514	2528	glucocorticoid	glucocorticoid	NN
2529	2536	actions	action	NNS
2536	2537	.	.	.

2538	2542	This	this	DT
2543	2548	study	study	NN
2549	2557	suggests	suggest	VBZ
2558	2562	that	that	IN
2563	2566	the	the	DT
2567	2574	pattern	pattern	NN
2575	2577	of	of	IN
2578	2599	pro-/antiinflammatory	pro-/antiinflammatory	JJ
2600	2608	cytokine	cytokine	NN
2609	2618	secretion	secretion	NN
2619	2622	may	may	MD
2623	2628	alter	alter	VB
2629	2632	the	the	DT
2633	2641	response	response	NN
2642	2644	of	of	IN
2645	2653	patients	patient	NNS
2654	2656	to	to	TO
2657	2671	glucocorticoid	glucocorticoid	NN
2672	2679	therapy	therapy	NN
2679	2680	.	.	.